

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM526880

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
NovoCure Limited		04/24/2019	Corporation: JERSEY
RECEIVING PARTY DATA			
Name:	Novocure GmbH		
Street Address:	Park 6		
City:	Root D4		
State/Country:	SWITZERLAND		
Entity Type:	Corporation: SWITZERLAND		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Serial Number:	88169359	NCOMPASS	
Serial Number:	88385697	NOVOCURE	
Registration Number:	5616214	NOVOCURE	
Registration Number:	4899330	OPTUNE	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	215.864.8175		
Email:	frankenfieldb@ballardspahr.com		
Correspondent Name:	Beth Frankenfield, Ballard Spahr LLP		
Address Line 1:	1735 Market Street 51st Floor		
Address Line 4:	Philadelphia, PENNSYLVANIA 19103		
NAME OF SUBMITTER:	Beth Frankenfield		
SIGNATURE:	/Beth Frankenfield/		
DATE SIGNED:	06/07/2019		
Total Attachments: 13			
source=Novocure Trademark Assignment Agreement (April 2019)#page1.tif			
source=Novocure Trademark Assignment Agreement (April 2019)#page2.tif			
source=Novocure Trademark Assignment Agreement (April 2019)#page3.tif			
source=Novocure Trademark Assignment Agreement (April 2019)#page4.tif			

CH \$115.00 88169359

source=Novocure Trademark Assignment Agreement (April 2019)#page5.tif
source=Novocure Trademark Assignment Agreement (April 2019)#page6.tif
source=Novocure Trademark Assignment Agreement (April 2019)#page7.tif
source=Novocure Trademark Assignment Agreement (April 2019)#page8.tif
source=Novocure Trademark Assignment Agreement (April 2019)#page9.tif
source=Novocure Trademark Assignment Agreement (April 2019)#page10.tif
source=Novocure Trademark Assignment Agreement (April 2019)#page11.tif
source=Novocure Trademark Assignment Agreement (April 2019)#page12.tif
source=Novocure Trademark Assignment Agreement (April 2019)#page13.tif

TRADEMARK ASSIGNMENT AGREEMENT

This TRADEMARK ASSIGNMENT AGREEMENT (the "Assignment"), effective as of April 24, 2019, is by and between NovoCure Limited, a corporation organized under the laws of Jersey, with its principal place of business located at Second Floor, No. 4, The Forum, Grenville Street, St. Helier, Jersey and a former address at Le Masurier House, La Rue Le Masurier, St. Helier, Jersey ("Assignor"), to Novocure GmbH, a corporation organized under the laws of Switzerland and registered under the number CHE-237.890.967 with its principal place of business located at Park 6, Root D4, Switzerland ("Assignee").

WHEREAS, Assignor owns directly or indirectly the Assigned Trademarks (as defined below);

WHEREAS, Assignor desires to assign, and Assignee desires to acquire all worldwide right, title, and interest in and to the Assigned Trademarks and the parties wish to record such acquisition to the extent required in the respective Patent Offices and/or relevant official offices, registrars, and registries around the world.

NOW, THEREFORE, for good and valuable consideration described in that certain Asset Transfer Agreement dated April 24, 2019 by and between Assignor and Assignee, the receipt and sufficiency of which is hereby acknowledged, Assignor and Assignee agree as follows:

1. Assignment of Trademarks. Effective as of the date hereof, Assignor transfers, conveys, assigns and delivers to Assignee and Assignee accepts all right, title, and interest of Assignor in and to (i) the trademarks and trademark applications set forth in Schedule A hereto as well as any unregistered trademarks currently used by Assignor, together with the goodwill of the business associated with the use of and symbolized by such trademarks; (ii) all renewals and extensions of any such application, registration and filing; (iii) all licenses for the use of the trademarks; (iv) all income, royalties, damages, claims, and payments now or hereafter due or payable under and with respect thereto, including, without limitation, damages, claims, and payments for past, present, and future infringements thereof; (v) all rights to sue for past, present, and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing; (vi) all rights corresponding to any of the foregoing throughout the world; and (vii) the right to assign the rights conveyed herein, the same to be held and enjoyed by Assignee for its own use and benefit, and for the benefit of its successors, assigns, and legal representatives (the "Assigned Trademarks").

2. Further Assurances. Assignor shall promptly do, make, execute, or deliver, or cause to be done, made, executed, or delivered, all such further acts, documents, and things as are necessary to transfer ownership of the Assigned IP to Assignee and for Assignee to record or register the Assigned IP with the relevant official office or registry.

4. Successors. This Assignment shall inure to the benefit of and is binding upon the respective successors and assigns of Assignor and Assignee.

5. Governing Law. This Assignment shall be governed by, and construed in accordance with (i) the laws of the United States, in respect to United States trademark, patent and copyright issues, and (ii) in all other respects, including as to validity (except for patent,

trademark and copyright issues), interpretation and effect, by the laws of the Switzerland without giving effect to the conflict of laws rules thereof.

6. Counterparts. This Assignment may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same agreement.


[Signature page follows]

A handwritten signature or mark, possibly initials, located in the bottom right corner of the page.

IN WITNESS WHEREOF, Assignor and Assignee caused this Assignment to be duly executed as of the date first written above.


ASSIGNOR:

NOVOCURE LIMITED

By: 
Name: Wilco Groenhuyzen
Title: Chief Financial Officer

ACCEPTED BY:

NOVOCURE GMBH

By: 
Name: Wilco Groenhuyzen
Title: Managing Director


Schedule A - Trademarks



April 19, 2019

SCHEDULE

NOVOCUR LIMITED TRADEMARK PORTFOLIO

MARK	COUNTRY	SERIAL NO. / Date REGISTRATION NO.	CLASS GOODS/SERVICES	STATUS
	Switzerland	SN: 80068/2018 Filed: 10/18/2018	IC35: Providing information about the administration of patient reimbursement programs designed to assist patients regarding medical treatment payment plan options; assistance to patients regarding treatment payment plan options, namely, administration of patient reimbursement programs IC36: Providing patient support services, namely, providing insurance information to help patients understand their insurance and plan benefits and providing insurance reimbursement assistance to eligible patients IC41: Medical educational services, namely, providing individualized and group instruction for patients and caregivers of patients requiring treatment of solid tumor cancers; Educational services, providing of training and education, namely, providing information to caregivers in the areas of patient support services and information about therapies for cancer treatment, all of the aforesaid provided via telephone, e-learning and personal training sessions, and non-downloadable webinars and printed material distributed in connection therewith	PENDING


DM/EAST #35724925 v2



April 19, 2019

SCHEDULE

NOVOOCURE LIMITED TRADEMARK PORTFOLIO

MARK	COUNTRY	SERIAL NO. / Date REGISTRATION NO.	CLASS GOODS/SERVICES	STATUS
	United States	SN: 88169359 Filed: 10/25/2018	<p>Class 35: Providing information about the administration of patient reimbursement programs regarding medical treatment payment plan options for patients undergoing treatment of solid tumor cancers in the nature of TTF device treatment; assistance to patients regarding treatment payment plan options, namely, administration of patient reimbursement programs for patients undergoing treatment of solid tumor cancers in the nature of TTF device treatment</p> <p>Class 36: Providing patient support services, namely, providing insurance information to help patients understand their insurance and plan benefits and providing insurance reimbursement assistance to eligible patients, all of the foregoing services related to patients undergoing treatment of solid tumor cancers in the nature of TTF device treatment</p> <p>Class 41: Medical educational services, namely, providing individualized and group instruction for patients and caregivers of patients undergoing treatment of solid tumor cancers in the nature of TTF device treatment; Educational services, namely, providing information to caregivers in the areas of patient support services and information about therapies for treatment of solid tumor cancers in the nature of TTF device treatment, all of the aforesaid provided via telephone, e-learning and personal training sessions, and non-downloadable webinars and printed material distributed in connection therewith</p>	PENDING

DMEAST #93724825 v2



April 19, 2019

SCHEDULE

NOVOCCURE LIMITED TRADEMARK PORTFOLIO

MARK	COUNTRY	SERIAL NO. / Date REGISTRATION NO.	CLASS GOODS/SERVICES	STATUS
NCOMPASS	China	SN: 33961342 Filed: 10/11/2018	IC35: Business management of reimbursement programs for others; business information; business management of reimbursement programs for others; professional business consultancy; business management assistance; business information; providing business information via a web site; commercial information and advice for consumers [consumer advice shop]; updating and maintenance of information in registries; systemization of information into computer databases	PENDING
NCOMPASS	Japan	SN: 2018-123564 Filed: 10/1/2018	IC35: Providing information about the administration of patient reimbursement programs designed to assist patients regarding medical treatment payment plan options; assistance to patients regarding treatment payment plan options; namely, administration of patient reimbursement programs; business management analysis or business consultancy; marketing research or analysis; providing information concerning commercial sales IC41: Medical educational services, namely, providing individualized and group instruction for patients and caregivers of patients requiring treatment of solid tumor cancers; Educational services, providing of training and education, namely, providing information to caregivers in the areas of patient support services and information about therapies for cancer treatment, all of the aforesaid provided via telephone, e-learning and personal training sessions, and non-downloadable webinars and printed material distributed in connection therewith; educational and instruction services relating to arts, crafts, sports or general knowledge	PENDING

DMEFAST #33724925 X2

April 19, 2019

SCHEDULE

NOVOCURE LIMITED TRADEMARK PORTFOLIO

MARK	COUNTRY	SERIAL NO. / Date REGISTRATION NO.	CLASS GOODS/SERVICES	STATUS
NOVOCURE	Canada	SN: 1903446 Filed: 6/8/2018	Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers; Training services in the use and operation of a medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers and consultation relating thereto	PENDING
NOVOCURE	China	SN: 32932060 Filed: 8/16/2018	IC35: Retail or wholesale services for medical supplies; pharmaceutical, veterinary, health preparations and medical supplies retail or wholesale services	PUBLISHED
NOVOCURE	China	SN: 32940377 Filed: 8/16/2018	IC41: (Amended) Arranging and conducting of colloquiums; arranging and conducting of conferences; arranging and conducting of seminars; arranging and conducting of workshops [training]; arranging and conducting of in-person educational forums; lending library services; publication of texts, other than publicity texts	PENDING
NOVOCURE	European Union	SN: 17498833 Filed: 11/20/2017 RN: 17498833	IC10: Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers IC41: Training services in the use and operation of a medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers and consultation relating thereto	REGISTERED 3/19/2018 Renewal Due 11/20/2027
NOVOCURE	Israel	SN: 300943 Filed: 11/22/2017	IC10: Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers IC41: Training services in the use and operation of a medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers and consultation relating thereto	PENDING

DMEAST #35724925.YZ

April 19, 2019

SCHEDULE

NOVOCURE LIMITED TRADEMARK PORTFOLIO

MARK	COUNTRY	SERIAL NO. / Date REGISTRATION NO.	CLASS GOODS/SERVICES	STATUS
NOVOCURE	Japan	SN: 2017-157220 Filed: 11/29/2017	IC10: Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers, medical apparatus and instruments IC41: Training services in the use and operation of a medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers and consultation relating thereto	REGISTERED 9/14/2018 Renewal Due 9/14/2028
NOVOCURE	Switzerland	SN: 50320/2018 Filed: 1/10/2018	IC10: Medical apparatus and instruments; in particular medical apparatus for the production of tumor therapy fields (TTFields), electromagnetic fields) for the treatment of solid cancer tumors IC41: Arranging and conducting training, instructional and lecture events; in particular training and advisory services relating to the use, use and application of medical apparatus and instruments for the production of tumor therapy fields (TTFields), electronic magnetic fields) for the treatment of solid cancer tumors	PENDING
NOVOCURE	United States	SN: 87864623 Filed: 4/5/2018 RN: 5616214	IC10: Medical device that delivers tumor treating fields, in the nature of electrical fields, to treat solid tumor cancers	REGISTERED 11/27/2018
NOVOCURE	U.S.	SN: 88385697 Filed 4/15/2019	IC10: Medical device that delivers tumor treating fields, in the nature of electrical fields, to treat solid tumor cancers IC41: Training services in the use and operation of a medical device that delivers tumor treating fields, in the nature of electrical fields, to treat solid tumor cancers and consultation relating thereto	6-Year Declaration due 11/27/2024 PENDING

DMEAST #85724825 v2

April 19, 2019

SCHEDULE

NOVOCCURE LIMITED TRADEMARK PORTFOLIO

MARK	COUNTRY	SERIAL NO. / Date REGISTRATION NO.	CLASS GOODS/SERVICES	STATUS
NOVOCCURE OPTUNE	China	SN: 32940390 Filed 8/16/2018	IC10: Medical apparatus and instruments; apparatus for use in medical analysis; testing apparatus for medical purposes; diagnostic apparatus for medical purposes; body rehabilitation apparatus for medical purposes; Sterilization of medical devices; galvanic therapeutic appliances; physiotherapy apparatus; ice bags for medical purposes; orthopedic articles; thread, surgical	PUBLISHED
OPTUNE	China	SN: 32923056 Filed 8/16/2018	IC10: (Amended) Thread, surgical	PENDING
OPTUNE	European Union	SN: 13436911 Filed: 11/6/2014 RN: 13436911	IC10: Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers	REGISTERED 3/31/2015 Renewal Due 11/6/2024
OPTUNE	Israel	SN: 269517 Filed: 11/9/2014 RN: 269517	IC10: Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers; all included in class 10	REGISTERED 6/2/2016 Renewal Due 11/9/2024
OPTUNE	Japan	SN: 2014-093406 Filed: 11/6/2014 RN: 5805705	IC10: Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers; medical apparatus and instruments	REGISTERED 11/13/2015 Renewal Due 11/13/2025
OPTUNE	Macau	SN N/149630 Filed 1/22/2019	IC10: Medical device that delivers tumor treating fields, in the nature of electrical fields, to treat solid tumor cancers	PUBLISHED

DMEAST #83724925.V2

April 19, 2019

SCHEDULE

NOVOCURE LIMITED TRADEMARK PORTFOLIO

MARK	COUNTRY	SERIAL NO. / Date REGISTRATION NO.	CLASS GOODS/SERVICES	STATUS
OPTUNE	Switzerland	SN: 669056/2014 Filed: 11/6/2014 RN: 669056	IC10: Surgical and medical apparatus and instruments; medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers	REGISTERED 2/2/2015 Renewal Due 11/6/2024
OPTUNE	Taiwan	SN 10/084459 Filed 12/28/2018	IC10: Medical device that delivers tumor treating fields, in the nature of electrical fields, to treat solid tumor cancers	PENDING
OPTUNE	United States	SN: 86437407 Filed: 10/28/2014 RN: 4899330	IC10: Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers	REGISTERED 2/9/2016 Renewal Due 2/9/2026
OPTUNE 150 KHZ	China	SN: 32927353 Filed 8/16/2018	IC10: (Amended) Thread, surgical	PENDING
OPTUNE 200 KHZ	China	SN: 32928842 Filed 8/16/2018	IC10: (Amended) Thread, surgical	PENDING
OPTUNE BY NOVOCURE	China	SN: 32932087 Filed: 8/16/2018	IC10: Medical apparatus and instruments; apparatus for use in medical analysis; testing apparatus for medical purposes; diagnostic apparatus for medical purposes; body rehabilitation apparatus for medical purposes; Sterilization of medical devices; galvanic therapeutic appliances; physiotherapy apparatus; ice bags for medical purposes; orthopedic articles; thread, surgical	PUBLISHED 1/27/2019

DMEAST #95724925 v2

April 19, 2019

SCHEDULE

NOVOCCURE LIMITED TRADEMARK PORTFOLIO

MARK	COUNTRY	SERIAL NO. / Date REGISTRATION NO.	CLASS GOODS/SERVICES	STATUS
OPTUNE in Japanese Characters	Japan	SN: 2015-078221 Filed: 8/14/2015 RN: 5817879	(C10: Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers, medical apparatus and instruments	REGISTERED 1/8/2016 Renewal Due 1/8/2026

DNEAST#35724925.v2

April 19, 2019

SCHEDULE B

NOVOCURE LIMITED TRADEMARK PORTFOLIO

MARK	COUNTRY	SERIAL NO. / Date REGISTRATION NO.	CLASS GOODS/SERVICES	STATUS
OPTUNE in Japanese Characters	Japan	SN: 2015-078221 Filed: 8/14/2015 RN: 5817879	IC10: Medical device that delivers tumor treating fields (electrical fields) to treat solid tumor cancers, medical apparatus and instruments	REGISTERED 1/8/2016 Renewal Due 1/8/2026

DMEAST #35724925 v2

